Abstract ND13: The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma

MLA

James A. Henderson, et al. “Abstract ND13: The Discovery and Characterization of CFT7455: A Potent and Selective Degrader of IKZF1/3 for the Treatment of Relapsed/Refractory Multiple Myeloma.” Cancer Research, vol. 82, June 2022, p. ND13. EBSCOhost, https://doi.org/10.1158/1538-7445.am2022-nd13.

APA

James A. Henderson, Scott J. Eron, Andrew Good, R Jason Kirby, Samantha Perino, Roman V. Agafonov, Prasoon Chaturvedi, Bradley Class, David Cocozziello, Ashley A. Hart, Christina S. Henderson, Marta Isasa, Brendon Ladd, Matt Schnaderbeck, Michelle Mahler, Adam S. Crystal, Roy M. Pollock, Christopher G. Nasveschuk, Andrew J. Phillips, … David A. Proia. (2022). Abstract ND13: The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma. Cancer Research, 82, ND13. https://doi.org/10.1158/1538-7445.am2022-nd13

Chicago

James A. Henderson, Scott J. Eron, Andrew Good, R Jason Kirby, Samantha Perino, Roman V. Agafonov, Prasoon Chaturvedi, et al. 2022. “Abstract ND13: The Discovery and Characterization of CFT7455: A Potent and Selective Degrader of IKZF1/3 for the Treatment of Relapsed/Refractory Multiple Myeloma.” Cancer Research 82 (June): ND13. doi:10.1158/1538-7445.am2022-nd13.